Green Key Biotechnology
Develops volumetric bioprinting (VBP) technology for contact-free, ultra-rapid 3D bioprinting of organoids and tissue engineering.
- CEO / Founder
- Maobin Xie
- Team Size
- 11-50
- Stage
- Active
- Total Funding
- $3M+
- Latest Round
- Angel
- Key Investors
- Bioisland Laboratory; Guangzhou Lihua Investment
Technology & Products
Key Products
Volumetric Bioprinters; Functional Bio-inks
Technological Advantage
Possesses over 1,000 m² of R&D space with equipment valued at tens of millions of RMB, focusing on the high-growth niche of volumetric bioprinting.
Differentiation
Value Proposition
Enables ultra-rapid, contact-free production of organoids and tissues using proprietary volumetric bioprinting and functional bio-inks, significantly reducing production time compared to layer-by-layer methods.
How They Differentiate
Utilizes a contact-free, visible-light-based volumetric bioprinting (VBP) process that completes centimeter-scale structures in ~60 seconds, maintaining ≥95% cell viability by eliminating the nozzle shear stress and UV exposure typical of extrusion or SLA-based bioprinting.
Market & Competition
Target Customers
Research institutions in organoids, tissue engineering, and regenerative medicine.
Industry Verticals
Biotech; Medical Research; Regenerative Medicine
Competitors
Readily3D; 3D Systems (Volumetric); Xolo
Growth & Milestones
Growth Metrics
Launched OrganMini, the first commercialized volumetric bioprinter in China; operates a 1,000+ sqm R&D facility with over 10 million RMB in specialized equipment.
Major Milestones
TCT Asia 2026 exhibitor; Development of VBP solutions; Established >1,000 m² R&D facility
Notable Customers
Guangzhou Medical University; Tsinghua University; Shanghai Jiao Tong University; Sun Yat-sen University Cancer Center